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p63, a p53 family member, is a tetrameric transcription factor required for the 
development and differentiation of stratified epithelia. Heterozygous mutations in 
p63 are causative of a group of autosomal dominant human disorders 
characterized by ectodermal dysplasia, orofacial clefting and limb malformations. 
More specifically, mutations clustering in the C-terminal domain of p63 cause 
Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC) syndrome, a life-
threatening disorder characterized by severe extended skin erosions.  
Here we show that multiple AEC-associated p63 mutations lead to protein 
misfolding and aggregation, as observed also in human keratinocytes isolated 
from an AEC patient and in mouse keratinocytes obtained from a conditional 
knock-in mouse model for AEC syndrome, recently generated in our laboratory, 
that phenocopies the skin clinical features found in human patients. In AEC mice 
the aggregated p63 mutant protein causes an impaired expression of endogenous 
p63 target genes, among which are keratins and desmosomal proteins involved in 
cell adhesion and in mechanical resistance, leading to severe skin fragility and 
erosions. Importantly, we found that abolishing the aggregation of p63, by 
introducing mutations that drastically reduce the aggregation propensity of AEC 
mutants, allowed to rescue p63 transcriptional functions, thus suggesting that 
impaired p63 transactivation activity is uniquely associated in AEC syndrome with 
exposure of aggregation-prone sequences. In addition, our studies focused on the 
therapeutic potential of these findings and suggested possible approaches to treat 
the AEC syndrome based on targeting and strengthening the endogenous protein 
disaggregation machinery or using drugs designed to chemically assist the correct 






1.1 The epidermal barrier: structure and functions  
The epidermis is a highly specialized epithelium involved in several 
fundamental protective functions: it prevents dehydration regulating the loss of 
water and solutes, participates in thermoregulation and, being the outermost 
compartment of the skin, it acts as physical barrier against mechanical trauma, 
ultraviolet radiations, chemical agents and microorganisms. The epidermal barrier 
is composed by multiple layers of keratinocytes, cells that undergo a series of 
morphological and physiological changes during epidermal maturation, giving rise 
to the complex architecture of the tissue. Four layers can be distinguished in the 
skin, from outside to inside: the cornified layer (stratum corneum), the granular 
layer (stratum granulosum), the spinous layer (stratum spinosum) and the basal 
layer (stratum basale), which is attached to the underlying basement membrane 
through a series of adhesion molecules such as hemidesmosome, integrins, 
laminin and anchoring fibrils (Fig. 1). The basement membrane forms a boundary 
of extracellular matrix between the epidermis and the underlying dermis.  
The stratified squamous epithelium of the epidermis is maintained by cell 
division within the basal layer. Here, epidermal stem cells ensure the self-renewal 
of the tissue giving rise to daughter stem cells and to transit amplifying cells, which 
display a more limited proliferative capacity and represent the major cells type in 
the basal layer of the developing and mature epidermis. After few doublings, some 
transit amplifying cells, generated by asymmetric mitoses, undergo a cell cycle 
arrest and initiate a terminal differentiation program. They first migrate outward in 
the spinous layer, where keratinocytes grow larger, establish robust intercellular 
connections (Simpson et al.,2011) and switch expression of basal layer specific 
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keratins, such as keratin 5 and keratin 14, to keratin 1 and keratin 10, typical of 
spinous layer (Fuchs and Green, 1980). Then, spinous keratinocytes differentiate 
to form the granular layer, where cells are characterized by the presence of 
numerous electron dense keratohyalin granules packed with the protein 
profilaggrin in their cytoplasm. Cells in the granular layer flatten, assemble a 
water-impermeable cornified envelope underlying the plasma membrane and 
express filaggrin (FLG) and loricrin (LOR), typical markers of the granular layer. 
Then, cornified envelope proteins, which are rich in glutamine and lysine residues, 
are synthesized and deposited under the plasma membrane of the granular cells. 
Cross-linking of structural proteins and lipids leads to the assembly of the highly 
cornified outermost layer of the epidermis, the stratum corneum. Finally, 
keratinocytes from the stratum corneum release lysosomal enzymes to degrade 
major organelles, including the nucleus. The dead stratum corneum cells create an 
impenetrable layer that is continually replaced (Fuchs, 2007). This continual 
stratification and differentiation of keratinocytes allows the epidermis maintenance 
and requires the coordinated and sequential regulation of several genes. Among 
these, the transcription factor p63 plays a crucial role in the early stages of skin 
development (Koster et al., 2004), being abundantly expressed in the basal layer 





Figure 1. The epidermis. The epidermis is a stratified squamous epithelium composed 
by four layers resting on the basement membrane, which separates the epidermis from 
the underlying dermis. During epidermal maturation keratinocytes undergo a terminal 
differentiation driven by a gradual and sequential expression of specific cytoskeletal and 
junction proteins, which underlies the tissue morphogenesis. Desmogleins (DSG1, DSG2, 
DSG3, DSG4) and desmocollins (DSC1, DSC2, DSC3) are desmosomal cadherins that 
bind to plakoglobin (PG) and plakophilin (PKP) for the assembly of the desmosomes. 
Desmoplakin (DP) anchors keratin intermediate filaments to desmosomal plaques.  











1.2 The transcription factor p63, a master regulator of epidermal 
development  
TP63 gene encodes a tetrameric transcription factor that plays an essential 
role in the commitment of simple ectoderm to epidermal lineages and is required 
for the development of stratified epithelia (Koster et al., 2004; Nguyen et al., 2006; 
Truong et al., 2006). p63 belongs to the p53 family, consisting of three genes 
encoding the transcription factors p53, p63 and p73. The p53 family members 
share an highly homologous DNA binding domain (DBD), therefore, p63 binds to 
canonical p53 DNA-binding sites and shares some biological functions with the 
other members of the family (Vanbokhoven et al., 2011; Yang et al., 1998).   
TP63 gene consists of 16 exons located on chromosome 3q28. Two classes 
of p63 proteins are generated by two alternative promoters, TAp63 and ΔNp63, 
and each of them includes three distinct variants, α, β, and γ isoforms, resulting 
from alternative splicing events at 3’ end (Fig. 2). More specifically, TAp63 proteins 
contain an N-terminal transactivation domain which shares 25% of identity with N-
terminal region of full-length p53 (Yang et al., 2002). TAp63 is expressed at very 
low levels in most tissues, whereas it is constitutively expressed in female germ 
cells in a dimeric inactive conformation during meiotic arrest (Suh et al., 2006; 
Crum et al., 2010). Upon DNA damage TAp63 dimers turn into active tetramers 
leading to oocytes death (Deutsch et al., 2011). Otherwise, ΔNp63 lacks of the 
typical N-terminal transactivation domain, but it retains two cryptic transactivation 
domains: the region including the first 26 N-terminal amino acids and a PPxY motif 
corresponding to exon 11/12 (Helton et al., 2006). ΔNp63 is found in a tetrameric 
form and the  isoform is the most abundantly expressed in the basal layer of the 
epidermis and in other stratified epithelia, where it plays an essential role in 
keratinocyte proliferation (Truong et al., 2006; Senoo et al., 2007; Antonini et al., 
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2010), stratification (Koster and Roop, 2004; Truong et al., 2006)  and cell 
adhesion (Carroll et al., 2006; Koster et al., 2007; Ferone et al., 2013), but it 
suppresses terminal differentiation, being involved in coordinating a complex 
balance between keratinocyte self-renewal and differentiation (Nguyen et al., 
2006). Importantly, ΔNp63 is a transactivator for most epidermal target genes, but 
it can also act as a repressor for some genes (Antonini et al., 2010; De Rosa et al., 
2009; Ramsey et al., 2011). ΔNp63α has a crucial role also in embryonic 
development of stratified epithelia, as it is specifically expressed in the surface 
ectoderm at E7.5-E8, prior to Krt5 and Krt14 expression, and it continues to be 
expressed during skin development and in the basal proliferative layer in postnatal 
life (Laurikkala et al., 2006). The α isoform is the longest one and contains a 
sterile-α-motif (SAM) domain, encoded by exons 13 and 14 in the p63a gene, and 
a post-SAM (PS) domain, encoded by exon 14 and located downstream the SAM 
domain. The SAM domain is a putative protein interaction module present in a 
wide variety of proteins, whose function is still unknown. This domain commonly 
interacts with similar SAM domains by homo- and hetero-oligomerization 
(Stapleton et al., 1999; Thanoset al., 1999), but it can also mediate intermolecular 
association with nucleic acids, lipids or other proteins not containing SAM domain 
(Schultz et al., 1997; Serra-Pages et al., 1995). The PS domain is about the same 
length as the SAM domain and can be divided in two subdomains. The N-terminal 
subdomain (45 amino acids) contains a transcriptional inhibitory (TI) sequence that 
forms a closed inactive dimer with the TA domain (Coutandin et al., 2016; Straub 
et al., 2010). The C-terminal subdomain (25 amino acids) contains a sumoylation 




Figure 2. p63 gene and its isoforms. Schematic representation of p63 gene structure 
and isoforms.  Two alternative promoters give rise to TAp63 or DNp63 transcripts, 
whereas at the 3’ end alternative splicing events generate ,  or  isoforms. In the lower 
panel, protein domains conserved in p53 family are shown: Transactivation domain (TA), 
DNA binding domain, Oligomerization domain. SAM and PS domains in p63  isoforms 
are absent in p53 full-length gene. The percentage of identity between p53 and p63 










1.3 The C-terminus of p63 isoform 
As p53 family members, p63 and p73 possess a domain structure similar to 
p53 but can contain variable C-terminal extensions, resulting by alternative 
splicing events. More specifically, the full-length  isoformof p63 and p73 is 
characterized by a sterile -motif (SAM) domain at the C-terminus followed by a 
post-SAM (PS) domain, both not present in human p53. Furthermore, differently 
from p63 and p63isoforms, that display p53-like functions, p63 has little or no 
p53-like activity, suggesting that these C-terminal extensions could be responsible 
for functional differences between p63 and p53 (Thanos and Bowie, 1999). 
The SAM domain is composed by ~70 amino acids and consists of protein-
protein interaction modules found in a series of proteins involved in the regulation 
of developmental processes, signal transduction and transcription (Schultz et al., 
1997). Although SAM domains adopt similar folds, they are remarkably versatile in 
their binding properties. Some identical SAM domains can interact with each other 
to form homodimers or polymers. In other cases, SAM domains can bind to other 
related SAM domains, to non-SAM domain-containing proteins and even to RNA 
(Qiao et al., 2005).  
The solution structure of the C-terminal domain of human p63 (505-579) was 
solved through NMR spectroscopy. The resulting structure shows the 
characteristic five helix bundle topology observed in other SAM domains (Schultz 
et al., 1997). It includes helix 1 (α1; residues 514–521), helix 2 (α2; residues 527–
533), a short 310 helix (H3; residues 538–542), helix 4 (α4; residues 546–551), 
and helix 5 (α5; residues 556–573). The five helices are tightly packed together via 
an extended hydrophobic core and form a globular and compact structure. The N-
terminal (residues 505–508) and the C-terminal (residues 576–579) regions are 
found to be highly mobile in solution (Cicero et al., 2006).  
16 
 
Missense mutations in the SAM domain of p63 cause Ankyloblepharon 
Ectodermal defects Cleft lip/palate syndrome (AEC, OMIM 106260) and Rapp 
Hodgkin syndrome (RHS, OMIM 129400) (McGrafth et al., 2001; Kantaputra et al., 
2003), very similar to AEC one, that will be discussed later. The high resolution 
crystal structure of the p63 SAM domain was determined to investigate the effect 
of several AEC-associated mutations on the stability of the domain. The aliphatic 
isoleucine and leucine residues (I549, L553, L556, I573, I576, L584, L587, I589, 
I597 and I601), that are part of the compact hydrophobic core, are highly 
conserved in all SAM domains (Fig. 3a). Compared with the wild-type, AEC-
associated mutations L553F, C561G, C561W, G569V, Q575 and I576T are all 
significantly destabilizing, probably because of the structural features of the wild-
type protein (Fig. 3b). Mutation L553F, which is close to F552, would probably 
cause a severe steric clash between the two phenylalanine rings and result in 
overcrowding in the hydrophobic core (Sathyamurthy et al., 2011). However, for 
two AEC-associated SAM mutations, G534V and T537P, the main effect does not 
concern a structural disruption but instead a perturbation of the dynamical 
properties. Molecular dynamics (MD) simulation reveals that the two mutants 
acquire a degree of helical content higher than that of the wild type protein, 
excluding a structural collapse. In contrast, both mutants display a similar increase 
in flexibility in helix 4 and at the N-terminal region, suggesting that the pathological 
behavior of p63 observed in the presence of these mutations could be associated 
with the occurrence of new recognition properties induced by a varied flexibility 
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Figure 3. SAM domain of p63. a) CLUSTALW sequence alignment of SAM domains of 
p53 family members. Conserved residues are shown in red. Conserved and partially 
conserved hydrophobic residues are shown in black and grey, respectively. Conserved 
and partially conserved charged residues are shown in blue and light blue, respectively. 
The positions and type of AEC mutations are shown above the sequence alignment. A 
diagrammatic representation of the five helices is shown below the alignment. b) Ribbon 
representation of the p63 SAM domain showing the position of mutations that are 
associated with AEC syndrome. (adapted from Sathyamurthy et al., 2011). 
 
The PS domain is located after the SAM domain and contains two individual 
components: one that uses an intramolecular interaction mechanism to mask and 
inhibit the transactivation domain and another that is involved in sumoylation. More 
specifically, the N-terminal subdomain consists of 45 amino acids and is called 
also “Trans-Inhibitory Domain” (TID), as it binds the TA domain of p63 forming a 
close inactive conformation and blocking its transactivation function. This inhibitory 
mechanism is crucial in regulating quality control in oocytes, where TAp63is kept 
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in an inactive dimeric state and switches to the tetrameric active conformation 
upon DNA damage, inducing cell death (Deutsch et al., 2011). 
The intramolecular interaction mediated by the TID domain does not involve 
Np63 isoform, as it lacks of its own TA domain. However, since p63 
tetramerizes and can also form hetero-oligomers between different p63 isoforms, 
the TID domain of Np63 can interact with the TA domain of another protein 
within the tetramer, acting in a dominant-negative manner (Serber et al., 2002).  
The C-terminal portion of PS domain, composed by the last 25 amino acids, 
contains a sumoylation site IKEE (K637), targeted by SUMO-1 (Small Ubiquitin-
like Modifier 1) for proteasome mediated degradation (Fig. 4). Some mutations 
falling within the SAM and post-SAM domains of p63 can alter the sumoylation 
capacity and lead to a strong increase of the transcriptional activities of p63, 
suggesting that sumoylation has a negative effect on p63 transactivation function. 
The findings that Np63 protein levels are regulated by SUMO-1 and that this 
regulation is altered when the PS domain is mutated suggest that SUMO 
conjugation to p63 plays a critical role in regulating the biological activity of p63, by 
controlling its intracellular concentrations (Ghioni et al., 2005; Straub et al., 2010). 
NMR studies of the PS domain has shown that this domain lacks of a 
secondary structure. Interestingly, the TID domains of p63 and p73 display a low 
intrinsic aggregation propensity which confers self-aggregation ability to the wild-
type proteins also in the tetrameric form, as they remain readily accessible  








Figure 4. PS domain of p63. CLUSTALW sequence alignment of PS domains of 
various vertebrate and invertebrate species. Strictly conserved amino acids are labeled in 
red. The conserved IKEE sumoylation motif is labeled in blue. In invertebrate species the 




1.4 p63-associated disorders 
Heterozygous mutations in TP63 gene cause a group of autosomal dominant 
human syndromes characterized by various combinations of ectodermal dysplasia, 
orofacial clefting and limb malformations (Rinne et al., 2006). p63 transcription 
factor plays in fact an essential regulatory role in several developmental processes 
during embryogenesis, being required for the differentiation of ectodermal 
derivatives such as hair, nails, mammary glands, teeth (Mills et al., 1999). 
Furthermore, it transcriptionally activates Fgfr2 gene to sustain epithelial and 
mesenchymal proliferation during palatal growth (Ferone et al., 2012), Irf6 gene to 
regulate palatal fusion (Thomason et al., 2010), cell adhesion molecules Dsp, 
Dsc3, Dsg1 (Ferone et al., 2013), Pvrl1 and Pvrl4 (Mollo et al., 2015) to control 
epidermal cell junctions and, importantly, it maintains the apical ectodermal ridge, 
a stratified epithelium essential for limb development (Yang et al., 1999). 
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Accordingly, mice lacking the p63 gene(p63-/-) die soon after birth with severe 
defects of skin and all stratified epithelia and their derivatives, craniofacial 
abnormalities and impaired limb formation (Mills et al., 1999; Yang et al., 1999; 
Vanbokhoven et al., 2011). 
At least five different syndromes caused by mutation in p63 have been 
described: Ectrodactyly, Ectodermal defects-Cleft lip/palate syndrome (EEC, 
OMIM 604292), Ankyloblepharon-Ectodermal defects-Cleft lip/palate syndrome 
(AEC, OMIM 106260), Limb Mammary Syndrome (LMS, OMIM 603543), Acro-
Dermato- Ungual-Lacrimal-Tooth syndrome (ADULT, OMIM 103285) and Rapp- 
Hodgkin Syndrome (RHS, OMIM 129400). Furthermore, some p63 mutations can 
cause non-syndromic single malformations, such as Split Hand/Foot Malformation 
(SHFM4, OMIM 605289) (Ianakiev et al., 2000) and isolated cleft lip (NSCL) 
(Rinne et al., 2007). 
P63 mutations are generally clustered in specific domains for each syndrome 
or occur in the same domain but display distinct characteristics (Fig. 5), suggesting 
a genotype-to-phenotype correlation. Anyway, p63 syndromes share at least one 
of the three main phenotypic hallmarks of p63 syndrome family (Fig. 6): 
ectodermal displasia, orofacial clefting, limb defects (Rinne et al., 2006). 
 EEC represents a prototype of p63 syndromes as it combines all the 
phenotypical features described above and is mainly caused by point mutation in 
the DNA binding domain (DBD) of the p63 gene (Fig. 5) that most likely impairs 
the DNA-binding properties of the transcription factor (Celli et al., 1999). 
EEC phenotype includes abnormal development of ectodermal structures such as 
teeth, skin, hair, nails and sweat glands, orofacial clefting and limb malformations, 
more specifically ectrodactyly and syndactyly (Rinne et al., 2007). 
 LMS was the first p63 syndrome linked to chromosome region 3q27. 
Mutations causative of LMS are located in the N- and C-terminus of the p63 gene. 
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LMS phenotype is mainly characterized by malformations of the hands and/or feet, 
similar as in EEC, and hypoplastic nipples and mammary glands. Lacrimal duct 
obstruction, dystrophic nails, hypohydrosis and teeth defects are observed, 
although ectodermal defects are much less prominent than in EEC syndrome. Hair 
and skin defects are rarely detected whereas orofacial clefting, always in form of 
cleft palate, is present in 30% of LMS patients (van Bokhoven and Brunner, 2002). 
 ADULT syndrome phenotype is overall overlapping to LMS one, except for the 
absence of orofacial clefting and the presence of hair and skin defects. In some 
ADULT patients, a point mutation in exon 8, changing R298 in the DNA binding 
domain into either a glutamine or a glycine, has been found. Differently from EEC 
syndrome hot-spot mutations, R298 is not located close to the DNA-binding 
interface, thus mutation of this arginine does not affect DNA binding (Duijf et al., 
2002). Two other mutations are located in the N-terminus. 
 RHS share most features with AEC, but is differentially classified because of 
the lack of skin erosions and the absence of ankyloblepharon in Rapp-Hodgkin 
syndrome.  In both syndromes clefting in lip and/or palate is equally frequent 
whereas limb malformations are absent.  AEC and RHS mutations are located in 
the same region of the p63 protein, the C-terminus, and are either point mutations 
in the SAM domain or deletions in the SAM or PS domains (Celli et al., 1999; 
McGrath et al., 2001; Barrow et al., 2002; van Bokhoven and Brunner, 2002; 
Kantaputra et al., 2003). The strong overlap between AEC and RHS, in terms of 
localization of hot spot mutations and phenotype, suggests that they could be 
variable manifestations of the same clinical entity (Bertola et al., 2004; Rinne et al., 
2007). 
SHFM is non-syndromic disorder associated to several chromosomal loci in 
the human genome. About 10% of SHFM patients have a p63 mutation (Rinne et 
al., 2006) and it is used to refer to their condition as SHFM4 (Ianakiev et al.,2000). 
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SHFM4 is a pure limb malformation (ectrodactyly and syndactyly) condition, 
without orofacial clefting or ectodermal dysplasia. Several mutations dispersed 
along the p63 gene are causative of SHFM4, among which splice-site mutation 
(3’ss intron 4), missense mutations (R58C, K193E, K194E, R280C/H) and stop-
mutations (Q634X, E639X) (Ianakiev et al., 2000; van Bokhoven et al., 2001; 
Zenteno et al., 2005). Possibly, SHFM is caused by altered protein degradation, 
even though different degradation routes are involved (Rinne et al., 2007). 
 
 
Figure 5. p63 disease-causative mutations. Spectrum of some p63 mutations causative 
of the indicated disorders, color-coded for each disease (other p63 syndromes are not 
represented). EEC-associated mutations affect mainly the DNA binding domain whereas 







Figure 6. The three hallmarks of p63 syndrome family. Scheme of overlapping 
phenotypes found in p63 syndromes. EEC and LMS combines all the three phenotypical 
features, although in LMS ectodermal defects are less severe. AEC and RHS are mainly 
characterized by ectodermal dysplasia and orofacial clefting, whereas ADULT expresses 
ectodermal and limb defects (adapted from Brunner et al., 2002). 
 
 
1.5 The AEC syndrome 
Among the p63 syndromes, the Ankyloblepharon-Ectodermal defects-Cleft 
lip/palate (AEC) syndrome, also known as Hey-Wells syndrome, is characterized 
by the most severe skin symptoms, including congenital erythroderma, skin 
fragility, blistering and extensive erosions, often accompanied by crusting and 
secondary infection (Hay and Wells 1976; McGrath et al. 2001; Julapalli et al., 
2009). Widespread skin erosions typically appear at or soon after birth, involving 
the scalp, head and neck, skin folds, palms and/or soles leaving, in some cases, 
up to 70% denuded skin. By 4 – 5 years age erosions could disappear, except for 
the head and auricular region (Rinne et al., 2006). The symptoms affecting adult 
patients are palmoplantar hyperkeratosis and erosive palmoplantar keratoderma, 
that can lead to bleeding after long walks. 
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Although skin lesions are the distinctive signs of AEC syndrome, other 
features are also found such as congenital fusion of the eyelids (ankyloblepharon), 
ectodermal dysplasia with severe involvement of the skin and its derivatives (teeth, 
nails, mammary glands) and cleft palate with or without cleft lip, occurring with 
different penetrance (Fig. 7).  
More specifically, clefting occurs approximately in 80% of AEC patients, whereas 
ankyloblepharon occurs only in 44% of AEC cases. Hearing loss has been 
reported in about 40% of the patients. AEC patients have nail and teeth defects in 
about 75–80% of cases (Rinne et al., 2006).  
AEC syndrome mutations are mainly clustered in the C-terminal portion of p63 
(Fig. 5), either as missense mutations in the SAM domain and more rarely in the TI 
domain or as frame-shift mutations in the TI domain, that lead to an abnormal 
elongation of the protein (Rinne et al., 2009). The specific clustering of p63 
mutations and the uniqueness of the skin phenotype in AEC syndrome suggest a 
genotype-to-phenotype correlation, although little is known about the biological 
and molecular mechanisms underlying the skin erosions, that could be life-
threatening in some cases, leading to aggravated lesions with bleeding and 
infections. To date, treatment is limited to wound care and prevention of infections 





Figure 7. Clinical signs in AEC infants. a) AEC patient with a close up of reticulated 
scarring resulting from skin erosions healing processes. b) Scalp erosions hemorrhagic 
crusting, granulation tissue and secondary infection. c) Dystrophic fingernails of AEC 
patients, characterized by small nails with partial loss/absence and distal fraying of the 




1.6 AEC mouse model 
To characterize the functional and molecular alterations correlated to p63 
mutation in AEC syndrome, a first constitutive knock-in mouse model (p63+/L514F) 
was previously generated in our laboratory (Ferone et al., 2012). This model 
carries a leucine to phenylalanine substitution in position 514 (L514F) of the p63 
protein and closely phenocopies the clinical hallmarks of the human disorder 
(Ferone et al., 2012, Ferone et al., 2013) (Fig.8). The L514 amino acid was 
chosen as a representative AEC mutation site as it localizes in the first helix of the 
SAM domain, where it seems to be a critical site for p63 protein stability. Indeed, 
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L514 is found mutated in three different amino acids (phenylalanine, valine or 
serine) in AEC patients, so any mutation in this region is likely to affect the overall 
structure and stability of the protein by altering the packing of the helices. 
Moreover, the substitution of a leucine with a phenylalanine probably causes a 
severe steric clash with another close phenylalanine ring in the folded protein 
(McGrath et al., 2001; Rinne et al., 2007). 
Similar to AEC patients, p63+/L514F mice display hypoplastic and fragile skin, 
ectodermal dysplasia and cleft palate, associated with a reduced epithelial cell 
proliferation during development (Ferone et al., 2012). This phenotype is largely 
overlapped to that of Fgfr2b−/− mice, in which the impaired FGF signaling leads to 
defects of epithelial cell proliferation during embryonic development (Petiot et al, 
2003; Rice et al, 2004).  In agreement, Fgfr2b and Fgfr3b expression is 
downregulated in p63+/L514F mice, suggesting that impaired FGF signaling 
downstream of p63 is likely an important determinant of reduced ectodermal cell 
proliferation and defective epidermal self-renewing compartment in AEC syndrome 
(Ferone et al., 2012). Importantly, skin fragility, a typical feature of AEC patients, is 
found also in p63+/L514F mice and is associated in both, human and mouse AEC 
keratinocytes, to an impaired regulation of the desmosome genes Dsp, Dsc3 and 
Dsg1 (Ferone et al., 2013). 
Unfortunately, p63+/L514F mice die soon after birth because of the cleft palate 
and this neonatal lethality not allowing either the generation of a mouse line or the 




Figure 8. Phenotype of the AEC mouse model p63+/L514F. a) Hematoxylin and Eosin 
staining of sagittal sections of wild type (+/+, left panel) and p63+/L514F (+/L514F, right 
panel) newborn heads. Cleft of the secondary palate is indicated by the arrow. b) 
Hematoxylin and Eosin staining of dorsal skin of wild type and p63+/L514F mice at P0. 




1.7 Quality control of unfolded proteins 
The protein quality control (PQC) system consists of multiple chaperone and 
degradation pathways that cooperate to preserve protein homeostasis (or 
proteostasis) by ensuring a healthy and functional proteome (Sontag et al., 2017; 
Houck et al., 2012; Jeng et al., 2015).  
Molecular chaperones are proteins that transiently interact with various non-
native polypeptides, driving the acquisition of their folded conformation without 
being associated with them when in their native and functional state (Kampinga et 
al., 2010). More specifically, they play a crucial role in assisting the folding of 
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newly synthesized polypeptides to the functional conformation co-traslationally, as 
they exit the ribosome (Balchin et al., 2016; Chiti and Dobson, 2017). Chaperone 
functions are not restricted to the protein folding, but include also recognition and 
sorting of misfolded proteins to the various PQC compartments, by a cooperation 
with other  cellular structures, such as nuclear membrane, ER network and 
cytoskeleton (Sontag et al., 2017). For example, molecular chaperones can direct 
specific client proteins towards degradation via both proteasome and autophagy 
(Howarth et al., 2007; Carra et al., 2008). Importantly, they can stabilize or 
destabilize interactions between mature, folded proteins (Kampinga et al., 2010).  
Nascent polypeptides form folding intermediates when not properly 
chaperone-assisted toward to their native state. Unfolded intermediates may also 
accumulate in the case of genetic mutations that impair proper folding or under 
stress conditions (Chiti and Dobson, 2017) and are often aggregation prone, due 
to the fact that they typically expose hydrophobic amino acid residues and regions 
of unstructured polypeptide backbone that are mostly buried in the native state 
(Hartl et al., 2009). These intermediates can undergo different fates (Fig. 9): they 
can recover the native conformation by chaperones activity or, if re-folding fails, 
are degraded via proteosomal or autophagosomal pathways. Alternatively, the 
unfolded intermediates can form aggregates by self-aggregation or co-aggregation 
with other unfolded proteins or even with fully folded proteins in the cell (Mogk et 
al., 2018). Proteins can be recovered from aggregates via disaggregation 
machines to undergo re-folding or degradation. 
The accumulation of newly synthesized, unfolded or misfolded proteins can 
lead to endoplasmic reticulum (ER) stress, which induces the unfolded protein 




The UPRER consists of ER transmembrane sensors that are responsive to 
protein unfolding or misfolding. These sensors can be divided into three branches: 
inositol-requiring protein 1 (IRE1), protein kinase RNA (PKR)-like ER kinase 
(PERK) and activating transcription factor 6 (ATF6). Under basal conditions, IRE1, 
ATF6 and PERK are kept in an inactive state by the binding of a chaperone 
binding immunoglobulin protein (BiP) to the luminal domains of the sensors. Upon 
ER stress, BiP is titrated away from UPR sensors and recruited to the unfolded or 
misfolded proteins, leading to the UPRER activation (Frakes et al., 2017). More 
specifically, upon activation, IRE1 ribonuclease directs the splicing of an 
unconventional 26-nt intron from X-box binding protein 1 (Xbp1) mRNA to 
generate the spliced xbp1-s isoform, which is translated into a transcription factor 
involved in regulating the expression of genes such as chaperones. On the other 
hand, ER stress induces PERK autophosphorylation and homomultimerization. 
The active phospho-PERK subsequently phosphorylates the  subunit of  
eukaryotic translation initiation factor 2 (eIF2), leading to an inhibition of global 
transcription (Harding et al., 1999). However, phospho-eIF2 preferentially 
increases the translation of activating transcription factor 4 (ATF4), which activates 
the transcription of UPRER and pro-apoptotic genes such as C/EBP homologous 
protein (Chop) (Marciniak et al., 2004).  
A third branch of UPRER, mediated by ATF6, is activated upon ER stress. After 
the distruption of the binding to BiP, ATF6 is transported to the Golgi apparatus, 
where it is cleaved and then transported into the nucleus to induce the expression 
of Xbp1 and genes involved in ER-associated protein degradation (ERAD) 
(Yamamoto et al., 2007).  
Therefore, the UPRER plays an essential role in preventing misfolded protein 
accumulation and consequent aggregation, as it induces cell death if protein 





Figure 9. The proteostasis network (PN). The PN consists of three branches aimed to 
the maintenance of protein homeostasis: biogenesis (in green), conformational 
maintenance (in blue) and degradation (in red). The nascent polypeptide forms a folding 
intermediate that, if not properly driven to the native state by chaperones, can turn into a 
prone-aggregation unfolded or misfolded intermediate. This intermediate can be degraded 
by the ubiquitin-proteasome system (UPS) or can form toxic or less toxic-amorphous 
aggregates. The aggregates can be dissolved by the disaggregation machinery and 
proteins can be directed towards either re-folding or degradation via proteasome. 
Alternatively, not-dissolved aggregates can undergo autophagic clearance (adapted from 









1.8 The HSP70 chaperone machine  
Protein aggregates can interfere with cellular processes by depleting factors 
crucial for protein homeostasis (Hipp et al., 2014). Molecular chaperones play a 
crucial role in preventing unfolded protein aggregation by protecting interactive 
surfaces against aberrant interactions with other not-canonical molecular partners 
(Mayer and Bukau, 2005). However, under stress conditions aberrant unfolding 
proteins may elude the chaperones system control and undergo aggregation. 
When this happens, cell can respond by different strategies, including 
disaggregation with recover of the refolded protein or proteasomal degradation 
and autophagic clearance of protein aggregates (also termed “aggrephagy”; 
Yamamoto and Simonsen, 2011).  
The key component of the disaggregation machinery is the HSP70 chaperone. 
Heat shock 70 kDa proteins (HSP70s) are ubiquitous molecular chaperones that 
function in a myriad of biological processes, including polypeptide folding, 
degradation, translocation across membranes and protein–protein interactions 
(Kampinga et al., 2010). Given its mutifunctionality, HSP70 never works alone, but 
its activity is driven by a class of cofactors: the J proteins, also known as HSP40s. 
Historically, J proteins have been divided into three classes (known as DNAJA, 
DNAJB and DNAJC), although this classification does not reflect either the 
biochemical function or the mechanism of action of group members, but rather is 
based on shared domains and motives (Hageman et al., 2009). 
Generally, the J proteins orchestrate HSP70 functions by delivering specific 
client proteins to HSP70 in precise locations in the cell, thus determining their fate. 




According to the “canonical model” of the HSP70 machinery (Szabo et al., 
1994; McCarty et al., 1995; Laufen et al., 1999), J protein initially binds the 
unfolded client protein preventing its aggregation and delivers it to HSP70, 
stimulating also HSP70 ATPase activity. Then a nucleotide exchanging factor 
(NEF) binds to HSP70 causing the release of ADP and the subsequent binding of 
a new molecule of ATP. ATP binding induces  an HSP70 conformational change 
leading to the release of the client protein and the loading of a new J protein-
unfolded client complex and the cycle begins again. 
In metazoa, HSP70 exhibits an autonomous disaggregation activity, supported 
by class A and B-type DNAJ-proteins that enhances loading of HSP70 at the 
aggregate surface. HSP70 can favor the release of trapped polypeptides from the 
aggregate applying pulling forces and moving away from the aggregate. Binding of 
Hsp110, that acts as a NEF, recycles HSP70 to initiate new binding and pulling 
events (Mogk et al., 2018; Fig.10). 
Interestingly, some J proteins localize in precise compartments of the cell 
where they perform specific functions also in an HSP70-independent manner. 
More specifically, members of a subclass of the DNAJB family (particularly 
DNAJB6b and DNAJB8) act as suppressors of aggregation and toxicity of disease-
associated polyglutamine proteins and their anti-aggregation activity is performed 
also in the absence of HSP70 (Hageman et al., 2010). DNAJB6 is found into two 
isoforms: the shorter isoform (DNAJB6b) is present in both the nucleus and the 
cytosol, while the longer isoform (DNAJB6a) is exclusively nuclear (Hanai and 
Mashima, 2003) and displays effective anti-aggregation properties only on nuclear 






Figure 10. HSP70 Disaggregation Machinery. Unfolding stress conditions like heat 
shock can cause protein unfolding and the formation of amorphous aggregates.  A bi-
chaperone system formed by Hsp70 and HSP110, with the cooperation of DNAJA and 
DNAJB co-chaperones, solubilizes aggregated proteins. First, J proteins bind the 
aggregate (1), then recruit HSP70 at the aggregate surface (2). HSP70 moves away from 
the aggregate promoting the release and the folding of trapped polypeptides. Finally, 
HSP110 binds HSP70 and allows its recycle for a new disaggregation event (3) (adapted 













2. AIM OF THE STUDY 
My research activity was aimed to investigate the molecular mechanisms 
underlying the AEC syndrome, focusing on the structural and functional alterations 
of the transcription factor p63 in the presence of the AEC-causative mutations. 
More specifically, I evaluated the effects of these mutations on p63 protein 
conformation, transcriptional activity and DNA binding ability.  
In the second part of my work, I investigated potential approaches to 
specifically target the aberrant molecular events underlying the AEC phenotype, in 
order to lay the foundation for a therapeutic strategy. To this aim, I evaluated to 
strengthening the activity of the endogenous protein quality control system 

















3. MATERIALS AND METHODS 
 
3.1 Primary mouse keratinocytes isolation and cell cultures 
Primary keratinocytes were isolated from the epidermis of newborn mice. 2-3 
days old mice were euthanized by hypothermia by placing them in a 100mm Petri 
Dish under ice for 30-45 minutes. Then mice were washed once with distillated 
water and twice with 70% ethanol, being careful to remove completely the ethanol 
after washing. The skin was removed from each mouse under a tissue culture 
hood using first sterile surgical scissors to amputate the limbs and the tail and then 
a sterile scalpel to cut the skin along the dorsal midline from the head to the tail. 
Using sterile forceps, the whole skin was removed, washed in HBSS and flatten 
with the dermis down on a petri dish. Then the skin was incubated overnight at 
4°C floating on 2 ml of Dispase solution (0.80 U/mL Dispase II, 10 mM HEPES, 
0.075% sodium bicarbonate, antibiotic/ antimycotic in HBSS) to obtain epidermis-
dermis dissociation. Next day the epidermis was peeled away from dermis with 
forceps, placed in 2 ml of trypsin solution (0.125% trypsin, 0.1 mM EDTA in HBSS) 
and cut quickly into very small fragments with scissors to promote the enzymatic 
and mechanical dissociation of the tissue. The minced epidermis was incubated at 
37°C for 5 minutes. Then trypsin was inactivated by adding DMEM medium 
supplemented with 10% of FBS and the cell suspension was filtered in 70 m cell 
strainer to remove undigested tissue and floating fragments. The isolated 
keratinocytes were plated in collagen coated dishes in high calcium medium to 
enhance cell attachment. Next day, keratinocytes were washed twice with PBS to 
remove unattached cells and calcium residuals and grown at 34°C and 8% CO2 in 
low calcium medium (0.05 mM CaCl2) supplemented with 4% of calcium-chelated 
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Fetal Bovine Serum (FBS) and Epidermal Growth Factor (EGF), changing medium 
every day. 
Neonatal HDFn, H1299, HEK293T and Saos-2 cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS. Human 
primary keratinocytes HK, NHEK and AEC were grown in Epilife medium (Thermo 
Fisher Scientific).  
 
3.2 Mouse genotyping 
The conditional knock-in L514F mutant mice p63+/FloxL514F, p63FloxL514F/FloxL514F, 
K14Cre;p63+/FloxL514F (+/L) and K14Cre;p63FloxL514F/FloxL514F (L/L) genotyping was 
performed by PCR using DNA isolated from mouse tails.  
The oligonucleotides primers used for the screening of FloxL514F allele are:  
 
Forward primer (5’-3’): CAGCGTATCAAAGAGGAAGGAGA 
Reverse primer (5’-3’): AGCCAGAATCAGAATCAGGTGAC 
 
A 250bp band is expected for the wild-type mice, a 337bp band for the mutant 
homozygous mice and both bands for the heterozygous ones. 
To screen mice for the presence of Cre-recombinase, the following 
oligonucleotides primers were used: 
 
Forward primer (5’-3’): GGCAGTAAAAACTATCCAGCAACA 
Reverse primer (5’-3’): TAACATTCTCCCACCGTCAGTA 
 




 3.3 Adenoviral infection  
Confluent primary keratinocytes (106 cells in 60mm dish) newly-isolated from 
p63+/FloxL514F or p63FloxL514F/FloxL514F conditional knock-in mice were infected 5 days 
after plating with adenovirus carring Cre-recombinase or GFP as control at MOI 
100 (provided by Okairos). Cells were incubated with the adenovirus for 2h at 
34°C and 8% CO2 in serum-free low calcium medium (1.2 ml of medium for a 
60mm dish). Then LCM supplemented with serum and EGF was added to the 
adenovirus mix up to a volume of 3 ml and left overnight at 34°C and 8% CO2. 
Next day the adenovirus was removed and fresh medium was added. Cells were 
collected 4 days after infection. 
 
 
3.4 Retroviral preparation  
High-titer retroviruses were produced in HEK293T cells by transient co-
transfection of pBABE p63 constructs or pMXs-KLF4 plasmid and amphotropic 
viral envelope plasmid (pAmpho). Cells were plated on collagen coated-60mm 
dishes the day before transfection. Subconfluent cells were co-transfected using 
6g of pBABE or pMXs constructs and 6g of pAmpho plasmid in the presence of 
30ul of Lipofectamine 2000 (Thermo Fisher Scientific), according to the 
manufacturer’s instructions. Cell supernatants containing the retroviruses were 
collected 48 hr after transfection, then fresh medium was added and collected 
again 72 hr after transfection. Finally, the retrovirus preparation was filtered using 





3.5 Retroviral infection 
Mouse primary keratinocytes newly-isolated from wild type mice (C57BL/6 
strain) were infected the day after plating at 50% confluence in 35mm dish with 
retroviruses carrying p63, produced as described above, in the presence of 8 
μg/ml Polybrene. Cells were incubated in the retrovirus mix for 2 hr at 34°C and 
8% CO2. Since retroviruses were produced in the high-calcium medium of 
HEK293T cells, keratinocytes were washed twice with PBS after infection to 
remove calcium residuals and then low calcium medium was added.  
Cells were infected for two consecutive days and 48h after the second 
infection were selected with 1μg/ml puromycin. After 48 hr uninfected control 
keratinocytes were died and infected cells were collected for RT-qPCR and 
Western blot analysis. 
 
 
3.6 HDFn-to-iKCs conversion assay 
2.4 x 106 neonatal HDFs were plated in 35mm dish and co-infected at 30% 
confluence, the day after plating, with retroviruses carrying p63 and KLF4 (Chen et 
al., 2014) in the presence of 8 μg/ml Polybrene. Cells were incubated in the 
retrovirus mix for 2 hr at 37°C. The next day a second infection was performed. 
Cells were then splitted into two 60mm dishes and selected with 2 μg/ml 
puromycin 48 hr after the second infection, changing medium supplemented with 
puromycin at alternate days until the uninfected control cells were died (48 hr after 
the start of selection). HDF-to-iKCs conversion was assessed 18 days after 




3.7 RNA isolation and RT-qPCR  
Total RNA was extracted from cells using TRIzol reagent (Thermo Fisher 
Scientific) and retro-transcribed to cDNA using SuperScript Vilo (Thermo Fisher 
Scientific). RT-qPCR was performed using the SYBR Green PCR master mix 
(Thermo Fisher Scientific) in an ABI PRISM 7500 (Thermo Fisher Scientific). 
Target genes were quantified using the following specific oligonucleotide primers 
and normalized for human RPLP0 expression or for mouse -actin expression: 
Oligonucleotide primers for Real Time RT-PCR 
Gene Forward 5’-3’ Reverse 5’-3’ 
hRPLP0 GACGGATTACACCTTCCCACTT GGCAGATGGATCAGCCAAGA 
hKRT14 GGATGACTTCCGCACCAAGT TCCACACTCATGCGCAGGT 
hIRF6 CAGCTCTCTCCCCATGACTGA CCCATACTCCTTCCCACGATAC 
m-act CTAAGGCCAACCGTGAAAAGAT GCCTGGATGGCTACGTACATG 
mKrt5  CAACGTCAAGAAGCAGTGTGC TTGCTCAGCTTCAGCAATGG 





mIrf6  CAGCTCTCTCCCCATGACTGA CCCATACTCCTTCCCACGATAC 
mFgfr2  TGGATCGAATTCTGACTCTCACA TTCGAGAGGCTGGGTGAGAT 
mSmad7  AACGAGAGTCAGCACTGCCA GAAGGTGGTGCCCACTTTCA 








For Chromatin immunoprecipitation (ChIP), 3 x 106 HEK293T cells were fixed  
with 1% formaldehyde in growth medium at 37°C for 10 minutes. Extracts were 
extensively sonicated with BIORUPTOR (Diagenode) at 4°C to obtain DNA 
fragments ranging from 400 to 800 bp in length. Chromatin was 
immunoprecipitated using rabbit antibodies for p63 (H-137; Santa Cruz 
Biotechnology) or rabbit IgG (Santa Cruz Biotechnology) as negative control. 
Bound chromatin was purified with Protein A Sepharose for 1hr at 4°C and then 
p63 binding sites in human KRT14 promoter were quantified by RT-qPCR using 
the following specific oligonucleotide primers and normalized to input (total 
chromatin): 
 
Forward primer (5’-3’):  GGGCCTGTCTGAGGAGATAGG 
Reverse primer (5’-3’): AGGCATGTTGAGAGGAATGTGA 
 
 
3.9 BN-PAGE, SDS-PAGE and Western Blot  
For BN-PAGE H1299 cells or mouse primary keratinocytes were scraped on 
ice in Native lysis buffer (25 mM Tris (pH 7.5), 150 mM NaCl, 2 mM MgCl2, 20 mM 
CHAPS, 1 mM DTT and protease inhibitors), collected and incubated 1h in ice in 
the presence of benzonase (Merck) for lysis and digestion of nucleic acids. Native 
lysates were then mixed with 20% Glicerol and 5mM Comassie G-250 and loaded 
on 3–12% Novex Bis-Tris gradient gel for BN-PAGE (NativePAGE system, 
Thermo Fisher Scientific), according to the product manuals. For SDS-PAGE, 
lysates were prepared in Laemmli buffer (10% glycerol, 0.01 % Bromophenol Blue, 
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0.0625 M Tris-HCl pH 6.8, 3 % SDS, 5 % ßmercaptoethanol), boiled and loaded 
on denaturing SDS-PAGE gel. To isolate nuclear and cytoplasmic extracts from 
keratinocytes, the extraction kit “NE-PER™ Nuclear and Cytoplasmic Extraction 
Reagents” (Thermo Fisher Scientific) was used following the manufacturer’s 
instruction. Protein concentration was then measured by Bradford assay and 8ug 
of each extract, nuclear or cytoplasmic, were loaded for SDS-PAGE. For Western 
Blot, proteins were transferred after run to Immobilon-P transfer membranes 
(Millipore) and probed with the antibodies diluted in PBS-0.2% Tween-20 with 5% 
nonfat-dry milk. The primary antibodies used for Western Blot analysis were: anti-
p63 (EPR5701), (Santa Cruz Biotechnology), anti-Keratin 14 (Covance), anti-
ERK1 (Santa Cruz Biotechnology) anti-ß-Actin (AC-15, Santa Cruz 
Biotechnology), anti-IRF6 (Ferone et al., 2012), anti-p53 (Ab6) Pantropic DO-1 
(Millipore), anti-PARP1 (Cell Signaling), anti--Tubulin (Sigma-Aldrich), anti-
HSP70/HSC70 (W27) (Santa Cruz Biotechnology), anti-V5 (Thermo Fisher 
Scientific), anti-FLAGM2 (Sigma-Aldrich). The following primary antibodies were 
diluted in TBS-0.2% Tween-20 with 5% Bovine Serum Albumin: anti-phospho-
PERK(Thr980) (Cell Signaling), anti-eIF2 (Cell Signaling), anti-phospho-
eIF2(Ser51) (Cell Signaling), anti-ATF-4(EPR18111) (Cell Signaling), anti-GADD 
153 (B-3) (Chop) (Santa Cruz Biotechnology). Secondary antibodies donkey anti-
rabbit or sheep anti-mouse IgG conjugated to horseradish peroxidase (HRP) (GE 






3.10 Luciferase reporter assay and p53-p63 DNA binding competition assay 
Luciferase assays in HEK293T cells were performed using the reporter 
constructs K14 promoter-luc (Candi et al., 2006) or FGFR2 enhancer-luc (Ferone 
et al., 2012), that carry firefly luciferase gene under the control of Keratin 14 
promoter and FGFR2 enhancer, respectively. 70% confluent cells were co-
transfected in 24-well dishes with the reporter construct and the plasmid encoding 
wild type or mutated Np63 at a ratio 1:3, using Lipofectamine 2000 (Thermo 
Fisher Scientific) following the manufacturer’s instruction.  
p53-p63 DNA binding competition assay was performed in Saos-2 cells using 
the reporter construct pG13Luc (el-Deiry et al., 1993), carrying firefly luciferase 
gene under the control of a p53 binding site that efficiently binds both p53 and 
p63, but is activated only by p53 and not by ΔNp63α (McGrath et al., 2001). 70% 
confluent cells were co-transfected in 24 well dishes with 125ng of pG13Luc 
plasmid and 20ng of pFLAG-CMV2-p53 with or without pFLAG-CMV2-Np63at 
different concentrations (10ng, 20ng or 40ng) using Lipofectamine 2000 (Thermo 
Fisher Scientific). 
In all the luciferase assays, Renilla Luciferase Vector (pRL-CMV; Promega) 
was co-transfected and Renilla activity was used to normalize transfection 
efficiency. Luciferase and Renilla activities were measured in the same sample 48 
hr after transfection using the dual-luciferase reporter assay kit (Promega). 
 
 
3.11 Co-Immunoprecipitation  
HEK293T cells were plated in collagen-coated 35mm dishes and co-
transfected at 95% confluence the day after plating with 1.5 g of pFLAG-CMV2-
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Np63a (wild type or mutant) plasmid and 1.5g of pcDNA5-FRT/TO V5 DNAJB1 
or DNAJB6a or DNAJB6b plasmid, using Lipofectamine 2000 (Thermo Fisher 
Scientific). After 48 hr, cells were washed twice with PBS and lysed in 500mL of 
Intermediate lysis buffer (50mM Tris-HCl pH 8, 150mM NaCl, 0.5% NP-40) with 
fresh-added protease and phosphatase inhibitors for 15 minutes on ice.  
Lysates were collected with a scraper and centrifuged at maximum speed for 
10 minutes at 4°C, to remove cellular debris. Supernatants were collected and 
10% of total lysate (Input) was kept for normalization. The immunoprecipitation 
was performed on the remaining lysate by adding 15 l packed-gel volume of anti-
FLAG M2 conjugated to agarose beads (Sigma), supplied 50% slurry and 
equilibrated with the Intermediate buffer just prior to use. After 2 hours of 
incubation in rotation at 4°C, unbound fraction was collected and the beads were 
washed 4 times with Intermediate lysis buffer plus PMSF and protease inhibitors. 
Finally, immunoprecipitated fraction was eluted by resuspension of the beads in 
Laemmli buffer 2X (20% glycerol, 0.02 % Bromophenol Blue, 0.125 M Tris-HCl pH 
6.8, 6 % SDS) and incubation at 65°C for 5 minutes. Samples were centrifugated 
and the supernatant was transferred in new tubes to discard the beads. 
For HSP70-p63 co-immunoprecipitation, H1299 were transfected at 95% 
confluence in 35mm dishes with 2 g of pcDNA3.1-Np63 (wild type or mutant) 
plasmid, using Lipofectamine 2000 (Thermo Fisher Scientific). After 24 hours, cells 
were washed and lysed as described above. 10% of Input was kept and the 
remaining lysate was incubated with anti-HSP70/HSC70 (W27) monoclonal 
antibody (Santa Cruz Biotechnology) overnight at 4 °C in rotation. Bound proteins 
were immunoprecipitated by incubation with Protein A Sepharose for 1hr at 4°C in 





3.12 Differentiation and PRIMA-1-Met and STIMA-1 treatment of human 
epidermal keratinocytes  
Keratinocytes were cultured at low density in Epilife medium with Human 
Keratinocyte Growth Supplement (HKGS). The differentiation process in vitro 
occurred when  cells reached the full confluence (covering 100% of the dish area). 
When keratinocytes became 100% confluent, the Epilife growth medium was 
swiched to Epilife medium supplied with 1.5 mM CaCl2, to sustain differentiation, 
and replaced every two days with fresh medium. Differentiated keratinocytes were 
observed at microscope taking pictures at different time points (3, 5, 7, 10 days of 
differentiation) to assess morphological changes. 
For PRIMA-1-Met / STIMA-1 treatments, subconfluent normal human 
epidermal keratinocytes (NHEK) or human keratinocytes derived from an AEC 
patient  (AEC keratinocytes) were treated with PRIMA-1-Met 30 M and/or STIMA-
1 10 M in Epilife medium with HKGS. After 48 hours they reached 100% 
confluence and the differentiation process started, sustained by the addition of  
1.5mM CaCl2 to the growth medium. The growth medium was replaced every two 
days with fresh medium containing CaCl2 and PRIMA-1-Met/ STIMA-1 compounds 
at the concentrations indicated above and keratinocytes were observed at the 











4.1 Mutations in p63 causative of AEC syndrome impair p63 transcription 
function 
P63 mutations causative of AEC syndrome cluster mainly in the carboxyl-
terminal domains of the protein and include missense mutations (e.g. L514F, 
C519R, G530V, D544Y in the SAM domain or R598L and D601V in the TI domain) 
and frameshift mutations that lead to abnormal extensions (e.g. 1709DelA, 
1859DelA, 3’ss intron 10, 1456InsA) of the protein. Mutations causative of other 
p63 syndromes are usually found in different sites along the protein and are likely 
to affect p63 function by different mechanisms. More specifically, EEC-associated 
mutations (e.g. R304Q) are mainly located in the DNA binding domain, thus 
compromising p63 binding to the DNA.  
To investigate the effect of AEC-associated mutations on p63 transcriptional 
functions we firstly tested the ability of a group of p63 mutants to transactivate the 
keratin 14 (KRT14) promoter by performing a luciferase reporter assay in 
HEK293T cells (Fig.11). As previously reported (Candi et al., 2006), Np63 
efficiently transactivated KRT14 promoter, whereas the EEC-associated mutant 
R304Q lost this function. All the tested AEC-associated mutations displayed an 
impaired transactivation ability. Interestingly, two missense mutations falling in the 
TI domain (Q630X, E635X) that are causative of SHFM retained the 
transactivation activity, indicating that they could affect p63 functions in other 




Figure 11. Transactivation activity of wild type p63 and p63 mutants. Luciferase 
reporter assay in HEK293T cells co-transfected with wild type p63 or the indicated p63 
mutants and the reporter vector carrying the firefly luciferase gene under the control of 
K14 promoter at a ratio 3:1. A Renilla luciferase control vector was co-transfected. Firefly 
and Renilla luciferase activities were measured sequentially from a single sample and 
Renilla luminescence was used to normalize firefly luminescence. (n=11). Data are shown 
as mean of independent samples ± standard error of the mean (SEM). Statistical 




To assess whether AEC mutations similarly affect p63 transcriptional activity in 
a more physiological context, as in epidermal keratinocytes, we took advantage of 
a conditional knock-in mouse model for AEC syndrome (p63+/floxL514F) generated in 
our laboratory, in which the AEC mutation L514F in exon 13 is expressed only in 
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the presence of the Cre recombinase. More specifically, the wild type exon 13 is 




Figure 12. Gene targeting strategy used for the generation of p63+/L514Fflox knock-
in mice. Schematic representation of target and knock-in alleles of p63+/L514Fflox mice. 
L514F mutation in exon 13 is indicated with *. In the target allele, LoxP sites (black 
triangles) flank wild-type exon 13 fused with the coding portion of exon 14 and the SV40 
polyA (13-14polyA, upper). Mutant exon 13 (in red) was placed downstream LoxP sites 
and 3xFLAG (in green) was added at the end of the coding sequence of exon 14 located 
downstream the mutant exon 13 (14-3xFLAG). FLAG-tagged p63 mutant protein is 
expressed upon Cre-mediated deletion of 13-14polyA portion (knock-in allele, lower). 
 
 
The conditional knock-in strategy allows to overcome the neonathal lethality 
due to cleft palate observed in the constitutive knock-in mouse model 
(p63+/L514F), previously generated in our laboratory (see Introduction section). To 
study the evolution of the skin phenotype in AEC mice, we crossed 
p63L514Fflox/L514Fflox mice with K14-Cre knock-in mice carrying the Cre recombinase 
gene under the control of the endogenous Krt14 promoter, that is active in 
stratified epithelia from embryonic day 17.5 (Huelsken et al., 2001). The generated 
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K14-Cre; p63L514Fflox/L514Fflox homozygous mice (L/L) fully recapitulate the skin 
defects and erosions found in AEC patients (Fig.13). 
 
Figure 13. Phenotype of K14-Cre; p63L514Fflox/L514Fflox mice. Upper panel: newborn K14-
Cre; p63L514Fflox/L514Fflox (L/L) mouse lacking of a large area of skin (representative of 10% of 
L/L mice at P0). Lower panel: wild type and L/L mice at P7. The mutant mouse displays 
skin crusting and erosions, with reduced body size and dehydratation (representative of 
100% of L/L mice at P7-P8). 
 
 
In addition, we measured the expression levels of epithelial p63 target genes 
in primary keratinocytes isolated from heterozygous p63+/L514Fflox and homozygous 
p63L514Fflox/L514Fflox mice, after infection with adenoviruses carrying the Cre 
recombinase (adeno-Cre) or the GFP (adeno-GFP) as control. Both real time RT-
PCR and Western blot analysis revealed that the expression of several genes 
known to be positively regulated by p63, including Krt14, Krt5, Fgfr2, Irf6 and Dsc3 
(Ferone et al., 2012; Ferone et al., 2013), were strongly reduced in homozygous 
keratinocytes (p63L514Fflox/L514Fflox) and to a lesser extent in heterozygous 
keratinocytes (p63+/L514Fflox), upon adeno-Cre infection (Fig.14A-B). Interestingly, 
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the expression of genes repressed by p63, such as Smad7 and Krt8 (De Rosa et 
al., 2009), was activated in the presence of the L514F mutation compared to the 
control (Fig. 13C), thus demonstrating that both transactivation and repression 
functions of p63 are impaired by AEC mutations.  
 
Figure 14. Transcriptional activity of heterozygous and homozygous p63L514F 
mutant compared to wild type p63 in mouse primary keratinocytes. A) Real time RT-
PCR of target genes induced by p63 in primary keratinocytes derived from p63+/floxL514F 
(het) and p63floxL514F/floxL514F (hom) mice, after infection with adenoviruses carrying Cre 
recombinase or GFP (ctr) (n=5). B) SDS-PAGE followed by Western blot for p63 and its 
target genes Krt14 and Irf6 in primary mouse keratinocytes treated as in (A).Erk was used 
as loading control. C) Real time RT-PCR of target genes repressed by p63 in primary 
mouse keratinocytes treated as in (A) (n=3). In (A) and (C) mRNA levels are normalized to 
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-actin expression. Ctr mRNA levels are set to 1. Data are shown as mean ± SEM. 
Statistical significance was assessed using one-way ANOVA analysis. *p ≤ 0.05; **p ≤ 
0.001; ***p ≤ 0.0001. 
 
 
4.2 AEC-associated mutations partially reduce p63 DNA binding ability 
We next investigated the causes of the impaired transcriptional activity 
observed in AEC-associated p63 mutants. To this aim, we tested the ability of 
AEC mutants to bind DNA by performing chromatin immunoprecipitation (ChIP) 
experiments with anti-p63 (H137) antibody in HEK293T cells transfected with wild 
type or mutant p63. P63 binding sites on KRT14 promoter were quantified by 
quantitative PCR (q-PCR) in the p63-bound chromatin and normalized to input. As 
previously reported, the EEC-associated mutant R304Q did not bind to well-
characterized p63 genomic binding sites in KRT14, whereas SHFM-associated 
mutants Q630X and E635X retained the DNA binding ability. Surprisingly, AEC 
mutants displayed a reduced binding to DNA, although AEC mutations do not 





Figure 15. DNA binding ability of wild type p63 and AEC-associated p63 mutants. 
ChIP-qPCR in HEK293T cells overexpressing p63 wild type and the indicated p63 
mutants on the KRT14 promoter (n=6). Immunoprecipitation was performed with anti-p63 
(H137) antibody and p63-bound chromatin was analyzed by qPCR using specific primers 
for p63 binding sites in KRT14 promoter. EEC-associated mutant R304Q was used as 
negative control. Data are calculated as percentage of total chromatin targeted by primers 
and are shown as mean of independent experiments ± SEM. Statistical significance was 
assessed using one-way ANOVA analysis. *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001. 
 
 
To further characterize the DNA binding ability of AEC mutants, we performed 
a p53-p63 DNA binding competition assay using the pG13Luc reporter construct 
containing the firefly luciferase gene under the control of a p53 binding site that is 
efficiently bound by both p53 and p63, but luciferase expression is activated only 
by p53 and not by ΔNp63(McGrath et al., 2001). Saos-2 cells, that are devoid of 
endogenous p53 and p63, were co-transfected with a fixed p53 concentration and 
increasing concentrations of p63 wild type or mutant in the presence of pG13-Luc 
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reporter construct. As expected, wild type p63 competed with p53 strongly 
impairing its transactivation activity, whereas the EEC mutant R304Q, being 
unable to bind to DNA, did not interfere with p53 transactivation at any tested 
concentration. On the other hand, AEC mutants L514F, D544Y and 1859DelA 
prevented p53 binding to DNA in a dose-dependent manner, indicating that they 
retained the ability to bind DNA, albeit with reduced efficiency compared to wild 
type p63 (Fig.16A). Samples were analyzed for Western blot to control p53 and 
p63 expression (Fig.16B). 
Taken together, these results indicate that the DNA binding ability of AEC 










Figure 16. DNA binding competition with p53 of wild type p63 or AEC-associated 
p63 mutants at increasing doses. A) Luciferase reporter assay in Saos-2 cells co-
transfected with p53 and wild type or mutant p63 at 2:1, 1:1 or 1:2 ratios in the presence 
of pG13-luc reporter construct. A Renilla luciferase control vector was co-transfected. 
Data were normalized for Renilla luciferase activity (n=3). Data are shown as mean ± 
SEM. Statistical significance was calculated using paired one-tailed t test. *p ≤ 0.05; **p ≤ 
0.01; ***p ≤ 0.001. B) SDS-PAGE followed by Western blot for p53 and p63 of the 






4.3 AEC-associated p63 mutant proteins form large aggregates in 
keratinocytes 
To deepen the mechanism by which AEC-associated mutations interfere with 
p63 functions we investigated the structural alterations specifically caused by AEC 
mutations, which exhibit a well-defined genotype-to-phenotype correlation. 
NMR studies performed in collaboration with the laboratory of Professor Volker 
Dötsch (Institute of Biophysical Chemistry, Goethe University of Frankfurt, 
Germany) revealed that AEC-associated p63 mutation L514F caused a less 
compact fold of the protein, leading to a destabilization of the SAM domain. In 
addition, p63L514F protein displayed a lower melting temperature and irreversibly 
precipitated upon unfolding induced by high temperature, in contrast to wild type 
p63, whose unfolding was reversible (data not shown). Importantly, these 
observations were associated to an increased aggregation propensity found in 
several AEC mutant p63 proteins analyzed using the TANGO algorithm, which 
predicts aggregation prone regions (APRs) in an amino acidic sequence.  
Next, we verified if protein aggregation occurred in AEC mutants 
endogenously expressed in epidermal keratinocytes. To this aim, we took material 
from the p63+/floxL514F knock-in mouse model for AEC syndrome, available in our 
laboratory, and from a patient affected by AEC syndrome, thanks to a 
collaboration with Prof. Daniel Aberdam (INSERM, Paris, France), who provided 
us the human keratinocytes.  
We performed BN-PAGE on keratinocytes lysates prepared in native 
conditions, followed by Western blot analysis for p63. As expected, in mouse 
keratinocytes derived from p63+/floxL514F and infected with adeno-GFP, wild type 
p63 mainly runs as a monomer. In contrast, in adeno-Cre–infected p63+/L514Fflox 
keratinocytes two forms were observed: the monomeric one and a large multimeric 
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assembly at high molecular weight (from 480 to 1048 KDa), which may referred to 
as “protein aggregate”. Finally, in Ad-Cre–infected p63L514Fflox/L514Fflox keratinocytes 
the monomeric form was lost and only the aggregated form was visible (Fig.17A). 
Similar results were observed in primary keratinocytes derived from Krt14-
Cre;p63+/L514Fflox and Krt14-Cre;p63L514Fflox/L514Fflox mice compared with wild type 
controls p63+/L514Fflox (Fig.17B). In AEC human keratinocytes, carrying the p63 
mutation T537P in heterozygosity, both the monomeric and the aggregated forms 
were detected. Conversely, in primary adult human keratinocytes (HK) and 
neonatal human keratinocytes (NHEK), both used as controls, wild type p63 run 
mainly as monomer (Fig.17C). 
 
Figure 17. Protein aggregates formed by AEC mutants in mouse and human 
primary keratinocytes. BN-PAGE (upper) and SDS-PAGE (lower) followed by Western 
blot for p63 on native lysates of primary keratinocytes. A) Primary keratinocytes derived 
from p63+/floxL514F (het) and p63floxL514F/floxL514F (hom) mice, after infection with adenoviruses 
carrying Cre recombinase or GFP (ctr). B) Primary keratinocytes derived from p63+/floxL514F 
(+/+), K14-Cre; p63+/floxL514F (+/L) and K14-Cre; p63floxL514F/floxL514F (L/L) mice. (C) Adult 
human keratinocytes (HK), normal human epidermal keratinocytes (NHEK) and primary 
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keratinocytes derived from an AEC patient carrying the heterozygous p63 mutation T537P 
(AEC).  
 
4.4 Transcriptional activity is restored by reducing the aggregation 
propensity of AEC-associated p63 mutant proteins 
In collaboration with Prof. Volker Dötsch we identified in p63 wild type and in 
some AEC-associated p63 mutants the aggregation-prone regions (APRs) using 
the TANGO algorithm. The analysis of wild type p63 sequence revealed a peak of 
-aggregation propensity in the TI domain, which was abolished when the 
substitution V603D was introduced (Fig.18B). The frameshift mutations 3’ss intron 
10, 1709DelA and 1809DelA caused the introduction of new aggregation-prone 
sequences (Fig.18A), whereas the missense mutations R598L and D601V led to 
an increase in the intrinsic aggregation propensity of the TI domain (Fig.18B). 
Therefore, the biochemical analysis of AEC-associated mutants indicated that the 
AEC mutations caused an alteration of p63 protein conformation leading to the 




Figure 18. Aggregation propensity of wild type p63 and AEC-associated p63 
mutants. A) Grafic representation of the aggregation propensity regions (APRs) predicted 
by TANGO algorithm in wild type Np63 (in black) and in the presence of the indicated 
AEC mutations 3’ss intron 10 (in orange) 1709delA and 1859delA (in yellow). B) Detail of 
APRs in the TI domain of p63 wild type (in black) and in the presence of AEC missense 
mutations R598L (in red) and D601V (in violet). The V603D variant (in blue) is predicted to 
abolish the intrinsic aggregation propensity of the TI domain. 
 
Subsequently, together with our collaborators, we identified amino acid 
substitutions or deletions that were predicted to reduce AEC mutants aggregation 
propensity using TANGO algorithm. We transfected AEC mutants carrying the 
mutations that were found to alleviate aggregation in H1299 cells and then we 
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analyzed the native lysates by BN-PAGE followed by Western blot for p63. 
Consistently with TANGO prediction, for the L514F mutant, aggregation was 
alleviated by the introduction of multiple amino acid substitutions in combinations 
(V603D/V511D/T533D). Single substitutions were also tested but they failed to 
prevent L514F mutant aggregation (Fig.19A). For 3’ss-int10, 1709delA and 
1859delA mutants aggregation was abolished by the deletion of APRs generated 
by the frameshift mutations (Fig.18A, Fig.19B). Finally, the introduction of the 
V603D substitution in the TI domain inhibited the aggregation of R598L and 
D601V mutants (Fig.19C).  
 
Figure 19. Aggregates formation of AEC-associated p63 mutant proteins with or 
without mutations or deletions predicted to reduce their aggregation propensity. 
BN-PAGE (upper) and SDS-PAGE (lower) followed by Western blot for p63 on native 
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lysates of H1299 cells transfected with wild type p63 or the indicated AEC-associated p63 
mutants (in red) or the AEC mutants carrying mutations or deletions that were predicted to 
prevent their aggregation by TANGO (in green).  
 
 
To verify whether the impaired transcription function observed in AEC-
associated p63 mutants was uniquely associated to protein aggregation, we tested 
the ability to transactivate KRT14 promoter of the not-aggregating AEC mutant 
variants, described above, compared to the corresponding AEC mutants, by 
performing a luciferase reporter assay in HEK293T cells. Data indicated that the 
L514F mutant bearing the triple substitution V603D/V511D/T533D displayed a 
restored transactivation activity compared to L514F mutant (Fig.20A). Similarly, 
the activities of 1709DelA and 1859DelA frameshift mutants were fully restored 
upon deletion of APRs in the elongated portion of the mutant proteins (Fig.20B). 
Finally, V603D substitution in R598L and D601V mutants preventing aggregation 
rescued also mutant p63 ability to transactivate (Fig.20C). Interestingly, V603D 
substitution alone, predicted to reduce the intrinsic aggregation propensity of the 







Figure 20. Transactivation activity of AEC-associated p63 mutants with or without 
mutations or deletions that prevent their aggregation. (A-C) Luciferase reporter assay 
in HEK293T cells co-transfected with wild type p63 or AEC-associated p63 mutants (in 
red) or not-aggregating AEC mutant variants (in green) and the K14 promoter-luc vector at 
a ratio 3:1. A Renilla luciferase control vector was co-transfected. Data were normalized 
for Renilla luciferase activity (n=3) (Upper). SDS-PAGE (Lower) followed by Western blot 
for p63 are shown as control. -actin was used as loading control. Data are shown as 
mean of independent samples ± standard error of the mean (SEM). Statistical significance 





To test the transcriptional activity of not-aggregating AEC mutant variants in a 
more physiological context, we resorted to a recently developed protocol to 
convert human dermal fibroblasts (HDFs) into induced keratinocyte-like cells 
(iKCs) by co-expression of ΔNp63α and the reprogramming factor Krüppel-like 
factor 4 (KLF4) (Chen et al., 2014). More specifically, we tested the ability of wild 
type p63, AEC mutants or not-aggregating AEC mutant variants to induce the 
expression of keratinocyte-specific p63 target genes, namely KRT14 and IRF6, 
thus leading to the conversion. HDFs were co-infected with retroviruses carrying 
wild type or mutant p63 and KLF4 and collected after eighteen days, required for 
the conversion into iKCs, for real time RT-PCR and Western blot analysis. In the 
presence of wild type p63 or V603D mutant, HDFs were converted into iKCs with 
the expression of KRT14 and IRF6 genes, measured as mRNA (Fig.21A) and 
protein (Fig.21B) levels. Consistently with previous observations, AEC mutants 
L514F, R598L and 1709DelA were unable to induce KRT14 and IRF6 expression 
and achieve the conversion. Interestingly, deleting the aggregation-prone peptides 
of the 1709DelA mutant or introducing V603D substitution into the R598L mutant 
fully rescued their ability to induce expression of KRT14 and IRF6 in HDF 
(Fig.21A,B). Although at lesser extent, alleviating aggregation of the L514F mutant 





Figure 21. HDF-to-iKC conversion assay in the presence of wild type p63 or AEC-
associated p63 mutants with or without mutations or deletions that prevent their 
aggregation. A) Real-time RT-PCR of keratinocyte-specific p63 target genes (KRT14 and 
IRF6) in HDFs converted to iKCs by co-infection with retroviruses carrying KLF4 
reprogramming factor gene and the indicated p63 mutants. B) Western blot of KRT14 and 
p63 in iKCs. β-actin was used as loading control. Data are shown as mean ± SEM and 
statistical significance was assessed using one-way ANOVA analysis. *P ≤ 0.05; **P ≤ 
0.001; ***P ≤ 0.0001. 
 
To further investigate the effects of not-aggregating AEC mutant variants in a 
keratinocyte physiological context, we measured the expression levels of Krt8 
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gene, repressed by wild type p63, in mouse primary keratinocytes infected with 
retroviruses carrying wild type p63, the AEC mutants L514F or R598L or the 
corresponding not-aggregating variants L514F/V603D/V511D/T533P or 
R598L/V603D, respectively. We collected the native lysates of keratinocytes to 
check for p63 aggregation by performing BN-PAGE followed by Western blot 
analysis and isolated RNA samples to measure Krt8 mRNA levels. We found that 
keratinocytes infected with L514F or R598L mutants displayed p63 aggregation 
(Fig.22A) and concomitant induction of Krt8 expression, as measured in both RNA 
(Fig.22B) and protein (Fig.22C) samples. Conversely, p63 aggregation and Krt8 
expression were suppressed in the presence of wild type p63 or not-aggregating 
AEC mutant variants L514FV603D/V511D/T533D and R598L/V603D (Fig.22A-C). 
 
Figure 22. Aggregation and transcriptional activity of AEC-associated p63 mutants 
with or without mutations predicted to reduce their aggregation propensity in 
mouse primary keratinocytes. A) BN-PAGE followed by Western blot for p63 in mouse 
primary keratinocytes infected with retrovirus carrying wild type p63 or the indicated p63 
mutants. B) Real time RT-PCR of Krt8 (n=4) and C) Western blot for Krt8 and p63 (lower 
panel) in mouse primary keratinocytes infected as in A. -actin was used as loading 
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control. Data are shown as mean ± SEM and statistical significance was assessed using 
one-way ANOVA analysis. * p ≤ 0.05. 
 
Taken together, these results indicated that AEC-associated p63 mutations 
cause an increased tendency to aggregate and the aggregation is responsible of 
the impaired transactivation activity of p63. Preventing aggregation rescued AEC 
mutant transcriptional functions. 
 
 
4.5 AEC mutant aggregates do not induce Unfolded Protein Response  
We next investigated the consequences of the AEC mutant protein aggregates 
for cellular homeostasis. More specifically, we evaluated whether the accumulation 
of AEC-associated mutants could elicit endoplasmic reticulum stress, leading to 
the activation of the Unfolded Protein Response of the Endoplasmic Reticulum 
(UPRER). To this aim we measured the activation of some crucial mediators of 
UPRER pathways in primary keratinocytes derived from K14-Cre; p63L514Fflox/L514Fflox 
homozygous mice (L/L) compared to wild type controls (CTR). As positive control 
of UPRER activation, we used wild type mouse primary keratinocytes treated with 
thapsigargin 1 M, a Ca2+-ATPase inhibitor that leads to ER Ca2+ depletion 
inducing ER stress. More specifically, we assessed PERK phosphorylation, which 
is induced upon PERK activation, and the downstream effectors P-eIF2, eIF2 
ATF4 and Chop in keratinocyte lysates by performing an SDS-PAGE followed by 
Western blot analysis (Fig.23). We observed that thapsigargin 1M induced 
phospho-PERK and ATF4 expression after 1 hour of treatment, whereas Chop 
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expression was induced after 4 hours of treatment, thus indicating that an UPRER 
activation occurred, as expected. On the other hand, none of the tested UPRER-
mediators was induced in L/L keratinocytes compared to CTR, suggesting that 
AEC mutant p63 accumulation did not cause an UPRER activation. 
 
Figure 23. Modulation of UPRER signaling mediators in the presence of wild type or 
AEC mutant p63 in mouse primary keratinocytes.  SDS-PAGE followed by Western 
blot in primary keratinocytes derived from p63floxL514F/floxL514F (CTR) or K14-Cre; 
p63floxL514F/floxL514F (L/L) mice for the following UPRER mediators: phosphorylated-
Perk (P-Perk), phosphorylated-eIF2 (P-eIF2), eIF2, Atf4 and Chop. Wild type mouse 
primary keratinocytes treated with thapsigargin 1M at different time points were used as 







4.6 AEC-associated p63 mutants interact with specific molecular chaperones 
involved in protein disaggregation 
To identify the proteostasis network involved in the cellular handling of AEC 
mutant aggregates, we focused on the molecular chaperones specifically recruited 
to AEC-associated p63 mutants to preserve protein homeostasis. We firstly 
verified the protein interaction of HSP70, a well-known molecular chaperone 
involved in many functions of the protein quality control (PQC) system, with wild 
type or mutant p63. We transfected wild type p63, AEC mutants L514F or R598L 
or EEC mutant R304Q in H1299 cells and performed an immunoprecipitation 
experiment using anti-HSP70 antibody. Then, we assessed p63 protein interaction 
with endogenous HSP70 by analyzing immunoprecipitated (IP) and total (Input) 
fractions by SDS-PAGE followed by Western blot for p63 and HSP70. As shown in 
input fractions, the expression levels of endogenous HSP70 remained unvaried 
upon expression of wild type or mutant p63 proteins. However, HSP70 displayed a 
strongly increased interaction with L514F and R598L AEC mutants and, to a 





Figure 24. Protein interaction of endogenous HSP70 chaperone with wild type p63, 
EEC-associated or AEC-associated p63 mutants. Co-immunoprecipitation between 
endogenous HSP70 and wild type or mutant p63 transfected in H1299 cells. 2.5 mg of 
total protein were immunoprecipitated using HSP 70/HSC 70 (W27) monoclonal antibody. 
Immunoprecipitated fraction (IP) was analyzed by SDS-PAGE and Western blot for 
HSP70 and p63. -actin was used as loading control. Input fraction is shown as control of 
HSP70 and p63 expression in the total lysate. 
 
 
HSP70 is involved in multiple biological processes ranging from protein folding 
to degradation and can act in the nucleus or in the cytoplasm. Therefore, to further 
characterize HSP70 interaction with AEC mutants, we firstly investigated whether 
aggregation occurred in the cytoplasm, where HSP70 could interact with p63 
mutant proteins in the attempt to assist their folding, or in the nucleus, where p63 
translocates to perform its functions. To this aim, we isolated nuclear and 
cytoplasmic extracts of keratinocytes derived from K14-Cre; p63+/floxL514F, K14-Cre; 
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p63floxL514F/floxL514F and control mice (p63+/floxL514F) and we analyzed them by SDS-
PAGE and Western blot for p63, to verify the cellular localization of wild type and 
mutant p63, and for HSP70 to assess whether the molecular chaperone could be 
recruited to the mutant protein and co-localize. Both wild type and mutant p63 
localized in the nucleus, whereas HSP70 distribution between nucleus and 
cytoplasm remained unvaried in the presence of p63 mutant protein, compared to 
the control, indicating that AEC mutants translocated into the nucleus where they 
formed large aggregates and were likely to interact with nuclear HSP70 (Fig.25). 
 
Figure 25. Nuclear/cytoplasmic localization of wild type p63, p63L514F mutant and 
HSP70 in mouse primary keratinocytes. SDS-PAGE followed by Western blot for p63 
and HSP70 on nuclear and cytoplasmic extracts of primary keratinocytes derived from 
p63+/floxL514F (+/+), K14-Cre; p63+/floxL514F (+/L) and K14-Cre; p63floxL514F/floxL514F (L/L) mice. 
PARP1 and -tubulin were used as nuclear and cytoplasmic markers, respectively. 
 
 
Among the other functions, HSP70 chaperone exhibits a disaggregation 
activity often supported by a cooperation with DNAJ-proteins. However, some 
DNAJ proteins can work independently from HSP70 and display anti-aggregation 
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properties, as discussed in the “Introduction” section. For this reason we tested the 
protein interaction of wild type and L514F mutant p63 with B-type DNAJ proteins 
that, as previously demonstrated (Hageman et al., 2010), are able to suppress 
protein aggregation, namely DNAJB1 and DNAJB6. The last one can be found into 
two isoforms: the longer DNAJB6a, acting in the nucleus, and the shorter 
DNAJB6b, acting in both nucleus and cytoplasm. FLAG-tagged wild type or L514F 
AEC mutant p63 were co-transfected with V5-tagged DNAJB1, DNAJB6a or 
DNAJB6b in HEK293T cells. Then, FLAG-tagged p63 was immunoprecipitated 
using anti-FLAG agarose beads and IP and Input fractions were analyzed by SDS-
PAGE followed by Western blot analysis for FLAG and V5 tags. DNAJB1 did not 
exhibit protein interaction either with wild type or with mutant p63. Interestingly, 
DNAJB6a displayed a stronger interaction with L514F mutant than with wild type 





Figure 26. Protein interaction between wild type p63 or p63L514F mutant and DNAJ 
proteins. A) Co-immunoprecipitation between FLAG-tagged wild type or mutant p63 and 
V5-tagged DNAJB1 or DNAJB6a co-transfected in HEK293T cells. B) Co-
immunoprecipitation between FLAG-tagged wild type or mutant p63 and V5-tagged 
DNAJB6b co-transfected in HEK293T cells. 3 mg of total protein were immunoprecipitated 
using anti-FLAGM2 agarose beads (Sigma-Aldrich). Immunoprecipitated (IP) fraction was 
analyzed by SDS-PAGE and Western blot for FLAG and V5 tags. Input fraction is shown 
as control of exogenous DNAJs and p63 expression in the total lysate. 
 
 
Taken together these data indicated that AEC mutants are bound by molecular 
chaperones involved in disaggregation functions but they elude the activity of PQC 
system in preventing or suppressing protein aggregation.  
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4.7 PRIMA-1-Met rescues the morphology of differentiated epidermal 
keratinocytes derived from an AEC patient 
The preliminary data shown above open new avenues to counteract 
aggregation and hopefully to rescue the skin defects in AEC syndrome, based on 
targeting the molecular chaperones that specifically interact with AEC mutants to 
potentiate their anti-aggregation activity.   
Alternatively, the proteostasis network can be enhanced using small 
molecules that bind to mutant proteins and assist the correct folding, acting as 
“pharmacological chaperones” (Powers et al., 2009). As a first attempt, we 
recently tested the effect of the small compounds APR-246 (also known as 
PRIMA-1-Met) and STIMA-1 on AEC mutant p63 functions. PRIMA-1-Met (p53-
dependent reactivation and induction of massive apoptosis) is able to restore 
mutant p53 apoptotic functions in human cancer cells (Bykov et al., 2002) and it 
has been demonstrated to rescue the epidermal differentiation of skin 
keratinocytes derived from EEC patients (Shen et al., 2013), targeting EEC-
associated mutant p63. STIMA-1 is a low molecular weight compound that 
reactivates mutant p53 in human tumor cells by stimulating its binding to the DNA 
(Zache et al., 2008).  
Based on the structural homology between p53 and p63, we evaluated the 
effects of the treatment with PRIMA-1-Met and STIMA-1, used separately or in 
combination, on human keratinocytes derived from an AEC patient carrying the 
p63 mutation T537P. In a preliminary screening, we tested the ability of AEC 
keratinocytes to undergo epidermal differentiation in vitro in the presence or in the 
absence of the small compounds. We previously observed that normal human 
epidermal keratinocytes (NHEK), but not AEC keratinocytes, were successfully 
induced to differentiate in vitro by high cellular confluence and high calcium 
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conditions. Keratinocytes were grown in Epilife medium containing Human 
Keratinocyte Growth Supplement (HKGS) until they reached 100% confluence. 
Then, the growth medium was switched to Epilife medium supplemented with 
HKGS and 1.5mM CaCl2 and cells were left to differentiate for 3, 5, 7 and 10 days. 
During the in vitro differentiation process, normal human epidermal keratinocytes 
enlarged, established closed cell-cell contacts and became flattened, largely 
recapitulating the differentiation steps of epidermal layers in vivo (Fig.27A). On the 
other hand, AEC keratinocytes displayed an impaired epidermal differentiation in 
vitro, as they largely retained the round shape characteristic of proliferating 
undifferentiated keratinocytes and, over the days of differentiation, they partially 
lost cell-cell connections acquiring an elongated morphology (Fig.27B). 
 
 
Figure 27. Morphology of normal human epidermal keratinocytes or AEC human 
keratinocytes undifferentiated and after 3, 5, 7 and 10 days of differentiation. 
Representative fields acquired using 10X magnification of normal human epidermal 
keratinocytes (A) and human keratinocytes derived from an AEC patient carrying the p63 
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mutation T537P (AEC T537P keratinocytes) (B). The epidermal differentiation process of 
keratinocytes started when cells became 100% confluent and was sustained by the 
addition of 1.5mM CaCl2 to the growth medium. Pictures were taken 3, 5, 7 and 10 days 
later.   
 
 
 Therefore, we assessed whether PRIMA-1-Met and/or STIMA-1 treatment 
could rescue the differentiated morphology of AEC keratinocytes. We treated also 
normal human epidermal keratinocytes with the compounds as control, to verify if 
the treatment could interfere with the differentiation process of wild type 
keratinocytes. Subconfluent keratinocytes were treated with PRIMA-1-Met 30 M 
and STIMA-1 10M, separately or in combination. After 48 hours, they reached 
100% confluence and the differentiation process was induced and sustained by 
the addition of 1.5 mM CaCl2 to the growth medium. The differentiation process 
was carried on for 10 days in the presence or in the absence (“not treated”) of the 
compounds. The morphology of differentiated normal human epidermal 
keratinocytes was not altered by the treatment with PRIMA-1-Met and/or STIMA-1 
compared to the not treated cells and no toxic effects were detected using the 
tested concentrations (Fig.28A). Interestingly, AEC keratinocytes dramatically 
changed their morphology upon treatment with PRIMA-1-Met compared to the not 
treated cells, forming a monolayer of enlarged and flatten cells similar to 
differentiated normal keratinocytes. Conversely, STIMA-1 worsened the 
morphology AEC keratinocytes, increasing the cell-cell detachment and leaving 
large holes in the dish. Combined PRIMA-1-Met and STIMA-1 treatment caused a 
sum of the effects derived from the single treatments, with cells enlargement and 





Figure 28. Morphology of  differentiated normal human epidermal keratinocytes or 
AEC human keratinocytes upon treatment with PRIMA-1-Met and/or STIMA-1. 
Representative fields acquired using 10X magnification of normal human epidermal 
keratinocytes (NHEK) (A) and human keratinocytes derived from an AEC patient carrying 
the p63 mutation T537P (B). Subconfluent keratinocytes were treated or not with PRIMA-
1-Met 30M  and/or STIMA-1 10M. After 48 hours they became 100% confluent,  the 
Epilife growth medium was switched to Epilife medium supplied with 1.5 mM CaCl2 and 
PRIMA-1-Met and STIMA-1 compounds and the differentiation process started. The 
growth medium was replaced every two days with fresh medium containing CaCl2 and the 
compounds. Pictures were taken 10 days later. 
 
 
These preliminary data indicate that PRIMA-1-Met rescued the differentiated 
morphology of AEC keratinocytes and, together with the previously published 
effects on mutants p53 and p63, encourage further investigation on structural and 





AEC syndrome is a rare autosomal dominant disorder caused by mutations in 
the TP63 gene. The severe skin fragility and extensive erosions represent 
distinctive signs of this p63-associated disorder. The skin lesions can be often life-
threatening and require an effective and targeted therapy that, to date, has not 
been found due also to the poor understanding of the molecular mechanisms 
underlying the disorder. Here we investigated the structural and functional 
consequences of p63 mutations causative of AEC syndrome, focusing on the 
implications for the p63 transcriptional activity on skin-specific target genes. 
We found that AEC-associated p63 mutants display an impaired 
transactivation activity, similarly to the EEC-associated R304Q mutant which is 
unable to bind to DNA, as previously reported (Celli et al., 1999). We observed 
also that AEC mutations cause a reduced DNA binding ability of p63, although, 
differently from EEC-associated mutations, they do not affect directly the DNA 
binding domain of the protein. Importantly, using a p53-p63 DNA binding 
competition assay we demonstrated that AEC mutants were able to interfere with 
p53 binding to DNA at increased doses compared to p63 wild type, whereas the 
EEC R304Q mutant did not compete with p53 at any tested concentration. These 
results indicate that DNA binding impairment is not an intrinsic property of the AEC 
mutants as is the case for EEC mutants, but rather an indirect consequence of 
structural aberrations in the protein, specifically caused by the AEC-associated 
mutations, which lead to a reduced p63 affinity for DNA. Interestingly, we found 
that two tested SHFM-associated mutations falling in the carboxyl-terminal domain 
of p63 did not impair either DNA binding or transactivation activity of p63, thus 
indicating that they interfere with p63 functions by different mechanisms.  
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These findings underline the close genotype-to-phenotype correlation which 
characterizes p63 syndromes. Despite the wide variety of p63 mutations 
associated to AEC syndrome, we found that all of them lead to conformational 
changes in p63 protein with the exposure of hydrophobic residues with a high 
aggregation propensity. AEC mutations can cause aggregation by either aberrant 
protein elongation introducing aggregation-prone peptides (e.g., 3’ss intron 10, 
1709DelA, 1859DelA), enhancing the intrinsic low aggregating-prone region (APR) 
of the TI domain (e.g., R598L, D601V) or by conformational changes that expose 
peptides with a natural high aggregation propensity (e.g., L514F). These 
evidences emerged at the first from the TANGO analysis of the predicted APRs in 
AEC mutant p63 proteins and then were confirmed also in cells. Importantly, we 
assessed that p63 aggregation occurs in human keratinocytes derived by an AEC 
patient. Furthermore, we have showed that p63 protein aggregation occurs in 
mammalian cells overexpressing AEC mutants as well as in primary keratinocytes 
derived from a newly developed conditional knock-in mouse model for AEC 
syndrome (p63+/floxL514F), recently generated in our laboratory, in which the L514F 
AEC mutation was expressed only in the presence of Cre recombinase. We 
induced the p63L514F expression in vitro, by infection of keratinocytes with 
adeno-Cre, or used keratinocytes isolated from mice which expressed p63L514F 
mutant in the skin (K14Cre; p63+/floxL514F), as they carried the Cre recombinase 
gene under the control of the K14 promoter. Our conditional knock-in AEC mouse 
model (K14Cre; p63floxL514F/floxL514F) fully recapitulates the skin defects and erosions 
found in AEC patients and allows to study the evolution of the skin phenotype in 
the adult avoiding cleft palate, another hallmark of AEC phenotype, which caused 
neonatal lethality in AEC constitutive knock-in mice (Ferone et al., 2012). We 
found that the expression levels of keratinocyte-specific p63 target genes, involved 
in the development and the differentiation of the skin, were reduced in AEC mouse 
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keratinocytes compared to wild type controls. Interestingly, some genes that are 
known to be negatively regulated by p63 (e.g., Smad7, Krt8) are induced in the 
presence of p63L514F mutant, thus indicating that protein aggregation impaired 
both transactivating and repressing functions of p63. 
 Of great relevance, we found that p63 transcriptional activity can be 
rescued by preventing aggregation upon deletion of aggregating peptides or 
introduction of specific amino acid substitutions that reduce the aggregation 
propensity of AEC mutants. These findings were confirmed in multiple assays and 
cellular systems and strengthen the idea that the impaired transcriptional functions 
of p63 and, consequentially, the fragile skin phenotype were uniquely caused in 
AEC syndrome by protein aggregation. 
 In a second part of the work, we investigated the effects of p63 aggregates 
on protein homeostasis. The Protein Quality Control (PQC) system responds to 
protein aggregation by different mechanisms to target aggregating proteins and 
assist their disaggregation. These mechanisms often involve the HSP70 molecular 
chaperone, which is provided of a standalone disaggregase activity supported by 
specific co-chaperones (Kampinga et al., 2010; Nillegoda et al., 2017). However, 
protein aggregates can also trap crucial components of the proteostasis network, 
which are rendered not available, thus leading to a reduced proteostasis capacity 
(Hipp et al., 2014). We observed that AEC-associated mutants and, to a lesser 
extent, EEC-mutant R304Q but not wild type p63 interact with endogenous 
HSP70, when overexpressed in H1299 cells. Interestingly, the expression levels of 
endogenous HSP70 remained unchanged upon expression of mutant or wild type 
p63, indicating that HSP70 is not upregulated in the presence of p63 mutant 
proteins, but it strongly interacts with aggregating- AEC mutants. Furthermore, we 
verified whether aggregation could compromise nucleocytoplasmic shuttling of 
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p63, evaluating also if HSP70 is recruited in the same compartment of the mutant 
protein. The analysis of nuclear and cytoplasmic extracts of keratinocytes derived 
from AEC mice revealed that mutant p63 localizes in the nucleus whereas HSP70 
is detectable in both nucleus and cytoplasm and its distribution between the two 
compartments is not altered in mutant keratinocytes compared to wild type 
controls. In addition, we assessed that AEC mutant p63 did not induce ER stress 
nor the activation of the Unfolded Protein Response of the Endoplasmic Reticulum 
(UPRER), thus suggesting that misfolded p63 mutant protein is not retained in the 
ER, but it translocates to the nucleus where it forms protein aggregates and 
interacts with nuclear HSP70. The interaction between HSP70 and aggregating 
AEC mutants opens to different interpretations. HSP70 could be recruited at the 
p63 aggregate surface, but it fails to execute protein disaggregation. On the other 
hand, HSP70 could be non-specifically trapped in p63 aggregates, therefore the 
chaperone availability could be reduced favoring further enrichment of 
aggregating-prone mutant p63 or possibly other proteins in the nucleus. However, 
a strengthened proteostasis machinery is required to eventually assist the correct 
folding of AEC mutant p63 and prevent protein aggregation. More specifically, our 
goal has been to identify  molecular chaperones or co-chaperones, specifically 
interacting with AEC mutants, whose activity could be enhanced to promote a 
targeted effect on p63.  
 The multifunctionality of HSP70 is often driven by DNAJ proteins co-
chaperones, which deliver specific unfolded client proteins to HSP70 stimulating 
also its ATPase activity (Kampinga et al., 2010). In addition, a subclass of the 
DNAJB family, particularly DNAJB6a, DNAB6b and DNAJB8, can display also 
anti-aggregating HSP70-independent functions (Hageman et al., 2010). 
Interestingly, we found that AEC mutant L514F, and not wild type p63, specifically 
interacts with DNAJB6a and DNAJB6b co-chaperones when co-overexpressed in 
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HEK293T cells. Importantly, both isoforms DNAJB6a and DNAJB6b act in the 
nucleus, where p63 aggregates accumulate.  
Taken together, these data provide new elements to design a targeted 
strategy aimed to prevent the aggregation of AEC-associated p63 mutant proteins, 
by selectively modulating the activity of AEC mutants interactors involved in the 
PQC system.  
Alternatively, a chemical approach could be used to deal with protein 
aggregation. Previous published studies demonstrated that small molecules were 
able to assist the correct folding and rescue the function of aggregating-mutant 
p53 in cancer (Bykov et al., 2002, Zache et al., 2008) or mutant p63 causative of 
EEC syndrome (Shen et al., 2013, Shalom-Feuerstein et al., 2013). Based on 
these studies, we tested the effects of PRIMA-1-Met (p53-dependent reactivation 
and induction of massive apoptosis) and STIMA-1 (SH group-targeting compound 
that induces massive apoptosis) on epidermal keratinocytes derived from an AEC 
patient carrying the p63 mutation T537P. We found that AEC keratinocytes 
displayed an impaired epidermal differentiation in vitro compared to normal 
keratinocytes and this impairment was morphologically rescued by the treatment 
with PRIMA-1-Met. Conversely, STIMA-1 or the combined PRIMA-1-Met/STIMA-1 
treatment caused more dramatic alterations of AEC keratinocytes morphology 
during differentiation. Therefore, this preliminary screening identifies PRIMA-1-Met 
as a small molecule potentially acting as a “pharmacological chaperone” for AEC 
mutant p63 proteins, encouraging to further investigate its effects at structural and 
molecular levels. 
In conclusion, our studies indicate that the AEC syndrome is a protein 
aggregation disorder and that reverting mutant p63 aggregation leads to a 
functional rescue. Importantly, our preliminary findings suggest potential 
80 
 
therapeutic approaches to obtain a phenotypical rescue in AEC patients, by 
increasing the proteostasis efficiency, using “proteostasis modulators”, or by small 
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